Pathogen-Reduction Tech Gets Some Focus At FDA Panel Meeting, But Not Enough, Cerus Says
Executive Summary
While a panel of US FDA experts agreed that pathogen reduction technology is a promising strategy for reducing blood platelet contaminations, they raised concerns about the cost of implementing the technology. The maker of the technology, Cerus, says the panel was under-briefed and distracted.